Atara Biotherapeutics (NASDAQ:ATRA) CAO Yanina Grant-Huerta Sells 2,414 Shares

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CAO Yanina Grant-Huerta sold 2,414 shares of the firm’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $9.13, for a total value of $22,039.82. Following the completion of the sale, the chief accounting officer directly owned 49,636 shares in the company, valued at approximately $453,176.68. The trade was a 4.64% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Atara Biotherapeutics Stock Up 0.4%

NASDAQ:ATRA opened at $9.45 on Thursday. The business’s 50-day moving average price is $5.98 and its two-hundred day moving average price is $8.97. Atara Biotherapeutics, Inc. has a twelve month low of $3.92 and a twelve month high of $19.15. The stock has a market cap of $85.14 million, a P/E ratio of -14.10 and a beta of -0.30.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.04. Atara Biotherapeutics had a negative return on equity of 79.12% and a negative net margin of 40.91%.The firm had revenue of $0.52 million for the quarter, compared to analysts’ expectations of $2.90 million. On average, equities research analysts expect that Atara Biotherapeutics, Inc. will post 0.2 EPS for the current fiscal year.

Institutional Investors Weigh In On Atara Biotherapeutics

A number of large investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its position in shares of Atara Biotherapeutics by 6.6% in the 3rd quarter. Vanguard Group Inc. now owns 203,438 shares of the biotechnology company’s stock worth $2,915,000 after buying an additional 12,677 shares during the last quarter. Marshall Wace LLP boosted its holdings in Atara Biotherapeutics by 28.4% in the fourth quarter. Marshall Wace LLP now owns 148,632 shares of the biotechnology company’s stock worth $2,689,000 after acquiring an additional 32,836 shares in the last quarter. Globeflex Capital L P boosted its holdings in Atara Biotherapeutics by 399.6% in the fourth quarter. Globeflex Capital L P now owns 77,224 shares of the biotechnology company’s stock worth $1,397,000 after acquiring an additional 61,766 shares in the last quarter. Mackenzie Financial Corp boosted its holdings in Atara Biotherapeutics by 183.5% in the third quarter. Mackenzie Financial Corp now owns 63,816 shares of the biotechnology company’s stock worth $914,000 after acquiring an additional 41,302 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Atara Biotherapeutics by 2.5% in the second quarter. Geode Capital Management LLC now owns 60,136 shares of the biotechnology company’s stock worth $464,000 after acquiring an additional 1,457 shares in the last quarter. 70.90% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on ATRA. Wall Street Zen raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Freedom Capital raised Atara Biotherapeutics from a “strong sell” rating to a “hold” rating in a report on Monday. Weiss Ratings reissued a “sell (d)” rating on shares of Atara Biotherapeutics in a report on Friday, March 27th. Finally, Canaccord Genuity Group set a $13.00 price objective on Atara Biotherapeutics and gave the company a “buy” rating in a report on Friday, May 8th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $9.50.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders.

The company’s lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers.